Biotech Values

[poorgradstudent]

I always think it's funny when an analyst's incorrect forecast on drug sales is publicly announced and practically blamed on the company. I would think it rather embarassing to miss forecasts as badly as UBS did. Just once, I'd like to read an analyst report that says "Wow, we really thought this drug was going to sell. But it hasn't, and we're dumb."

Also, the comment about Tarceva's slow down in share gains versus Iressa is really not useful without some data to back it up. Anecdotally, it appeared that Tarceva had done a great job of eclipsing Iressa's market. So mathematically, share gains must slow down as you theoretically approach 100%. I'd hate for the UBS analyst to confuse his readers with useless interpretations of script data.

Luckily I stopped buying and selling on investment recommendations long ago